Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): A multicentre phase III study with a double-blind, randomised withdrawal phase - Pivonello, R; Fleseriu, M; Newell-Price, J (Lancet Diabetes Endocrinol, 2020)